{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:02:18Z","timestamp":1759104138150,"version":"3.44.0"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"am","delay-in-days":309,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.psychres.2021.114147","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T20:44:51Z","timestamp":1627937091000},"page":"114147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Oral long acting antipsychotic penfluridol as a harm reduction treatment in a patient suffering from untreated schizophrenia and multiple drug dependence: A case report"],"prefix":"10.1016","volume":"304","author":[{"given":"Charles","family":"Daur\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maeva","family":"Fortias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Icick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9ment","family":"Delage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Bloch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Avril","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Vorspan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.psychres.2021.114147_bib0001","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3109\/03602537908993895","article-title":"Penfluridol: a neuroleptic drug designed for long duration of action","volume":"9","author":"Migdalof","year":"1979","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.psychres.2021.114147_bib0002","article-title":"Chlorpromazine versus penfluridol for schizophrenia","volume":"9","author":"Nikvarz","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.psychres.2021.114147_bib0003","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0920-9964(00)00063-3","article-title":"Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia","volume":"48","author":"Salyers","year":"2001","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.psychres.2021.114147_bib0004","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/15504263.2019.1579948","article-title":"Living with dual diagnosis and homelessness: marginalized within a marginalized group","volume":"15","author":"Sch\u00fctz","year":"2019","journal-title":"J. Dual Diagnosis"},{"key":"10.1016\/j.psychres.2021.114147_bib0005","article-title":"Penfluridol for schizophrenia","volume":"2","author":"Soares","year":"2006","journal-title":"Cochrane Database Syst. Rev."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178121004431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178121004431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T05:51:37Z","timestamp":1759038697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178121004431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":5,"alternative-id":["S0165178121004431"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2021.114147","relation":{},"ISSN":["0165-1781"],"issn-type":[{"type":"print","value":"0165-1781"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral long acting antipsychotic penfluridol as a harm reduction treatment in a patient suffering from untreated schizophrenia and multiple drug dependence: A case report","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2021.114147","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114147"}}